How did we get here?


LUMICKS was founded in 2014 as academic spin-off from the research group of Prof. Gijs Wuite, Prof. Erwin Peterman, and Prof. Iddo Heller at VU University Amsterdam. After returning from Berkeley and Stanford, Wuite and Peterman joined forces on single molecule analysis. By integrating force manipulation and measurement with high-resolution confocal imaging, they created the ability to correlate molecular activity with the molecule’s states and conformational changes. The ability to correlate the structure – function relationship proved highly valuable. With the help of Dr. Iddo Heller, super-resolution was added.

After significant interest from the market, LUMICKS was founded, and these technologies were commercialized and made easy to use with high throughput so that the power of dynamic single-molecule analysis could be put in the hands of biologists.

Expanding Across New Markets



  • First sales in South Africa & Australia, and new customers in TU Delft, University at Buffalo, Hong KongUniversity of Science and Technology, Semmelweis University, Ludwig Maxmillian University and many more
  • LUMICKS grows to 55 people
  • Established first Center for dynamic single-molecule drug research in partnership with AstraZeneca and University of Cambridge
  • Entered the immunology market with z-Movi for Cell avidity measurement and screening
  • Launched G2 product line & next gen Bluelake software
  • Developed Surface Assay toolkit for use in cell biology
LUMICKS Team (2018)

A Global Presence



  • Sales to Imperial College London, University of California Berkeley, Johns Hopkins University, University of Zurich
  • First Pharmaceutical Customers
  • 30% revenue from China
  • Opening of US Sales office
  • Series A funding
  • 38 FTEs
  • Investing in scale-up

Release of the m-Trap™ Optical Tweezers

Key Accounts & Broadening Technologies



  • Sales to Rockefeller University, AMOLF, ShanghaiTech University, University of Göttingen
  • Nature publication with C-Trap™
  • Organic growth
  • 2nd product line: AFS™
  • First C-Trap installations
  • 19 FTEs
  • Break even


Co-founder & CEO Olivier Heyning accepts the 2016 Young Start-up Award. Picture by Eric Brinkhorst

Breaking Through



  • First C-Trap™ sales following product introduction
  • 12 FTEs
  • Break-even

BIOCEV Prague & MPI-CBG, the first two C-Trap™ users

LUMICKS Incorporated



  • First component sale to Harvard
  • License agreement
  • LUMICKS Founded

Co-founder Andrea Candelli demonstrating LUMICKS Technology to State Secretary Sander Dekker

The First Steps



  • First Patent Filed
  • Publication in Nature on CTFM Technology
  • ERC Proof of Concept subsidy granted

Take your research to the next level.

Get exclusive news on the latest products, single-molecule events and breakthrough science.

Newsletter pop up
By clicking the subscribe button you agree to LUMICKS’ privacy policy.